SHC

In the past six months, Sotera Health reported strong Q2 2026 earnings in August 2026, exceeding market expectations with significant revenue growth and increased net income, leading to raised full-year guidance and strong stock appreciation. In May 2026, a secondary offering of 31,838,253 shares of common stock by certain selling shareholders was announced. Also in May 2026, Alton Shader was named Chief Executive Officer, with the previous CEO transitioning to Executive Chairman. Throughout this period, analysts maintained favorable ratings, with a consensus of 'Moderate Buy' and positive average price targets. The ongoing ethylene oxide (EtO) litigation and regulatory environment remain a material risk, though recent favorable court decisions suggest future litigation-related payments may be manageable, and the company continues to invest in compliance. Insiders sold approximately $24 million worth of company stock in the past three months.